02624nam 2200625Ia 450 991096652670332120200520144314.097816080547011608054705(CKB)2670000000271397(EBL)1058006(OCoLC)818819310(SSID)ssj0000914441(PQKBManifestationID)11472063(PQKBTitleCode)TC0000914441(PQKBWorkID)10863981(PQKB)11009670(MiAaPQ)EBC1058006(Au-PeEL)EBL1058006(CaPaEBR)ebr10621400(OCoLC)823743211(DE-B1597)731054(DE-B1597)9781608054701(EXLCZ)99267000000027139720121204d2012 uy 0engur|n|---|||||txtccrHow selegiline ((-)-deprenyl) slows brain aging /authored by Joseph Knoll1st ed.[s.l] Bentham Science Publishers20121 online resource (161 p.)Description based upon print version of record.9781608055944 1608055949 Includes bibliographical references and indexes.Cover; Title; EUL; Contents; Foreword; Abbreviations; Keywords; Introduction; Chapter 01; Chapter 02; Chapter 03; Chapter 04; Chapter 05; Chapter 06; Chapter 07; Chapter 08; Chapter 09; Summary and Conclusion; Epilogue; References; Appendix; Author Index; Subject IndexThis e-book is a reference on Selegiline ((-)-Deprenyl) effects on the brain. Selegiline, described in thousands of research papers, is registered in over 60 countries. At present, more than one hundred preparations containing selegiline circulate in the global market under different brand names. They are widely used in the treatment of Parkinson's disease, Alzheimer's disease, major depression and as a geroprotective / anti-aging drug. ((-)-Deprenyl) selegiline, the first selective inhibitor of B-type MAO which, in contrast to the known MAO inhibitors, did not potentiate the effect of tyraDepression, MentalBrainAgingSelegilineDepression, Mental.BrainAging.Selegiline.616.8527Knoll J(Jozsef)97889MiAaPQMiAaPQMiAaPQBOOK9910966526703321How selegiline ((-)-deprenyl) slows brain aging4344175UNINA